Search Results - "Calarota, S"

Nanochemistry-based immunotherapy for HIV-1 by Lori, F, Calarota, S A, Lisziewicz, J

“…Highly active antiretroviral treatment (HAART), i.e. the combination of three or more drugs against human immunodeficiency virus type 1 (HIV-1), has greatly…”
Get more information

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients by Calarota, Sandra, Bratt, Göran, Nordlund, Siv, Hinkula, Jorma, Leandersson, Ann-Charlotte, Sandström, Eric, Wahren, Britta

“…DNA vaccination is known to generate immune responses against HIV-1 in animal models. We aimed to assess the efficacy of DNA vaccination in induction of immune…”
Get full text

DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy by Hejdeman, B, Boström, A C, Matsuda, R, Calarota, S, Lenkei, R, Fredriksson, E L, Sandström, E, Bratt, G, Wahren, B

“…The aim of this study was to evaluate the immunological responses induced by DNA plasmids containing HIV regulatory genes administered in combination in…”
Get more information

Immune Responses in Asymptomatic HIV-1-Infected Patients After HIV-DNA Immunization Followed by Highly Active Antiretroviral Treatment by Calarota, Sandra A, Leandersson, Ann-Charlotte, Bratt, Goran, Hinkula, Jorma, Klinman, Dennis M, Weinhold, Kent J, Sandstrom, Eric, Wahren, Britta

“…Intensive chemotherapy is capable of reducing the viral load in HIV-1-infected individuals while infected cells are still present. A special property of DNA…”
Get full text

HIV subtypes and recombination strains-strategies for induction of immune responses in man by Wahren, B, Ljungberg, K, Rollman, E, Levi, M, Zuber, B, Kjerrström Zuber, A, Hinkula, J, Leandersson, A.-C, Calarota, S, Hejdeman, B, Bratt, G, Sandström, E

“…Clinical and experimental studies of HIV-1 subcomponents were made in order to increase their immunogenicity. HIV subtype envelopes A, B and C have been…”
Get full text

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity by Calarota, S A, Kjerrström, A, Islam, K B, Wahren, B

“…DNA plasmid immunization has the important advantage over traditional vaccines of making it possible to combine selected genes into one vaccine. The efficacy…”
Get more information

Maternal Antibodies to HIV‐1 Envelope Domains: No Correlation with HIV‐1 Vertical Transmission in Patients from Argentina by Calarota, S A, Libonatti, O V

“…The role of the maternal antibody response in relation to vertical human immunodeficiency virus type 1 (HIV‐1) transmission was investigated in HIV‐1‐infected…”
Get full text

Intensification and Stimulation Therapy for Human Immunodeficiency Virus Type 1 Reservoirs in Infected Persons Receiving Virally Suppressive Highly Active Antiretroviral Therapy by Kulkosky, Joseph, Nunnari, Giuseppe, Otero, Miguel, Calarota, Sandra, Dornadula, Geetha, Zhang, Hui, Malin, Anne, Sullivan, Julie, Xu, Yan, DeSimone, Joseph, Babinchak, Timothy, Stern, John, Cavert, Winston, Haase, Ashley, Pomerantz, Roger J.

“…Highly active antiretroviral therapy (HAART) has led to significant changes in mortality and morbidity in the human immunodeficiency virus type 1 (HIV-1)…”
Get full text

Cellular HIV-1 Immune Responses in Natural Infection and After Genetic Immunization by CALAROTA, Sandra A, WAHREN, Britta

“…By eliminating infected cells, virus-specific cytotoxic T-lymphocytes (CTL) play a central role in host protection. Many studies to date seem to support the…”
Get full text

Anti–T-cell Ig and mucin domain–containing protein 1 antibody decreases T2 airway inflammation in a mouse model of asthma by ENCINAS, J, JANSSEN, E, WEINER, D, CALAROTA, S, NIETO, D, MOLL, T, CARLO, D, MOSS, R

Get full text

Retrospective study of children born to HIV-1-infected mothers in a pediatric hospital in Argentina by Liberatore, D I, Avila, M M, Calarota, S, Libonatti, O, Pampuro, S, Carrillo, M G, Balbaryski, J, Sala, A M, Giraudi, V, Massa, B

“…The aim of this retrospective study, which included 103 children born to human immunodeficiency virus type 1 (HIV-1)- infected mothers, is to initiate a…”
Get more information

Normalizing ELISPOT to quantify human cytomegalovirus (HCMV) and Epstein Barr-virus (EBV) specific T-cell response in kidney transplant recipients: Presentation at ESCV 2016: Poster 157 by nara, C, Cassaniti, I, Calarota, SA, Adzasehoun, KMG, Scaramuzzi, L, Comolli, G, Baldanti, F

Get full text

Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects: Presentation at ESCV 2016: Poster 92 by Cassaniti, I, Calarota, SA, Adzasehoun, KMG, Chiesa, A, Comolli, G, Parea, M, Baldanti, F

Get full text

Evaluation of HPV16-specific central memory T cell response in healthy subjects and patients with head-neck cancer: Presentation at ESCV 2016: Poster 16 by Cassaniti, I, Calarota, SA, Adzasehoun, KMG, nara, C, Comolli, G, Barzon, L, Pedrazzoli, P, Baldanti, F

Get full text

Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals by Lisziewicz, Julianna, Bakare, Nyasha, Calarota, Sandra A, Bánhegyi, Dénes, Szlávik, János, Ujhelyi, Eszter, Tőke, Enikő R, Molnár, Levente, Lisziewicz, Zsolt, Autran, Brigitte, Lori, Franco

“…The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir immunization in HIV-infected subjects on fully suppressive…”
Get full text

Kinetics of T-Lymphocyte Subsets and Posttransplant Opportunistic Infections in Heart and Kidney Transplant Recipients by CALAROTA, Sandra A, ZELINI, Paola, TINELLI, Carmine, MARONE, Piero, BALDANTI, Fausto, DE SILVESTRI, Annalisa, CHIESA, Antonella, COMOLLI, Giuditta, SARCHI, Eleonora, MIGOTTO, Clara, PELLEGRINI, Carlo, ESPOSITO, Pasquale, MINOLI, Lorenzo

“…The potential use of T-lymphocyte measurements as infection risk markers after solid organ transplant has not been fully investigated. We analyzed the kinetics…”
Get full text

Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides by Pampuro, S E, Calarota, S A, Marquina, S A, Rabinovich, R D, Libonatti, O V

Get full text

Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants by Calarota, Sandra A., Weiner, David B.

“…It is clear that the development of a safe and effective vaccine for human immunodeficiency virus type 1 (HIV‐1) remains a crucial goal for controlling the…”
Get full text

Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo by Kulkosky, Joseph, Sullivan, Julie, Xu, Yan, Malin-Markham, Anne, Otero, Miguel, Calarota, Sandra, Zielinski, Jennifer, Culnan, Derek M, Pomerantz, Roger J

“…Three HIV-1-infected individuals, on virally-suppressive highly active anti-retroviral therapy (HAART), were treated in vivo with anti-retroviral inhibitor…”
Get full text

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model by Otero, Miguel, Calarota, Sandra A., Felber, Barbara, Laddy, Dominic, Pavlakis, George, Boyer, Jean D., Weiner, David B.

“…DNA vaccines have been effective at generating useful immune responses in many animal species. However, it is clearly desirable to increase their potency. The…”
Get full text